Renova Verification
- ✓≥99% purity by HPLC + mass spectrometry
- ✓Independent Janoshik 3rd-party analysis
- ✓−20°C lyophilized · 2–8°C reconstituted
← Back to catalog
Fat Loss & MetabolismAvailable
Tirzepatide
10 mg / vial
Format
Presentation — choose mg
$85 USD10 mg / vial
RD$5,100 · approx. $8.5/mg
Coming soon · reserve in advance and we will notify you as soon as it arrives.
💰 Buy by volume
3+ items
Save 10%
★ Wholesale
10+ of one
Save 35%
Discount applied automatically at checkout.
🧪 COA❄️ Cold chain🛡️ Replacement guarantee🔒 Secure payment📦 Nationwide shipping🇺🇸 cGMP · ISO 9001 guidelines · COA
Dual GIP/GLP-1 receptor agonist — FDA-approved molecule (Mounjaro/Zepbound) with proven clinical efficacy in body-mass reduction and glycemic control studies (Phase III SURMOUNT-1, NEJM 2022), backed by years of clinical data.
- Mechanism: Dual GIP/GLP-1 agonist (well-characterized receptors).
- Evidence: Robust in humans — Phase 3 (SURPASS/SURMOUNT), years of pharmacovigilance.
- In context: FDA-approved (Mounjaro/Zepbound). Renova supplies it for research only. GI effects; caution in pregnancy.
Research range · SC
2.5–15 mg · 1×/week (titrated)
🟢 Clinical evidence · titrated from a low dose
Ranges cited in research literature. Not a usage recommendation. For research use only.
🧪 Independent third-party analysis available — Janoshik Analytical (HPLC + MS).View all COAs →
This product is exclusively for research purposes. Not intended for human use, consumption, or therapeutic applications. For laboratory use only under qualified supervision.